Induction of Immunity to Feline Caliciviral Disease

Similar documents
CLINICAL RELEVANCE. Intervet Inc Intervet Lane Millsboro, DE 19966

Canine Distemper Virus

Vaccines for Cats. 2. Feline viral rhinotracheitis, FVR caused by FVR virus, also known as herpes virus type 1, FHV-1

Antibody Test Kit for Feline Calici, Herpes and Panleukopenia Viruses (2011)

BOVINE RESPIRATORY DISEASE COMPLEX. Kristen Mierzwiak LCS 630

Feline Respiratory Infections in Animal Shelters

4-year-old neutered male American domestic shorthair cat with a locally extensive area of swelling ulceration and crusting over the nasal planum.

ENVIRACOR J-5 aids in the control of clinical signs associated with Escherichia coli (E. coli) mastitis

Canine and Feline Distemper. Description. The following chart indicates the animals which are susceptible to infection by canine and feline distemp

Ip - Infectious & Parasitic Diseases

How to stop the snotty noses: Preventing feline upper respiratory infections. Staci Cannon, DVM, MPH, DACVPM, DABVP (Shelter Medicine Practice)

Canine Distemper Virus

Panleuk Basics Understanding, preventing, and managing feline parvovirus infections in animal shelters

Taking the Teeth Out of Canine Distemper Virus July 21, 2016

Parvovirus Type 2c An Emerging Pathogen in Dogs. Sanjay Kapil, DVM, MS, PhD Professor Center for Veterinary Health Sciences OADDL Stillwater, OK

SCIENTIFIC DISCUSSION

Clinical Manifestations and Treatment of Plague Dr. Jacky Chan. Associate Consultant Infectious Disease Centre, PMH

Three-Year Serologic Immunity against Canine Parvovirus Type 2 and Canine Adenovirus Type 2 in Dogs Vaccinated with a Canine Combination Vaccine*

Inactivation of Burkholderia mallei in equine serum for laboratory use.

INFECTIOUS HEPATITIS, PARVOVIRUS & DISTEMPER

Feline Viruses in Wildcats from Scotland

FELINE INFECTIOUS PERITONITIS Visions Beyond the Tip of the Iceberg!

Malignant Catarrhal Fever in a Red Angus Cow B Y : L A U R E N R I C E R O V C

Management of infectious diseases in shelters

Feline Leukemia By Richard G. Olsen

EUROPEAN REFERENCE LABORATORY (EU-RL) FOR BOVINE TUBERCULOSIS WORK-PROGRAMME PROPOSAL Version 2 VISAVET. Universidad Complutense de Madrid

Diurnal variation in microfilaremia in cats experimentally infected with larvae of

Update on diagnosis of feline infectious peritonitis (FIP)

IMMUNOLOGIC RESPONSES OF DOMESTIC AND BIGHORN SHEEP TO A MULTIVALENT PASTEURELLA HAEMOLYTICA VACCINE

Factors affecting plate assay of gentamicin

Field necropsy techniques in mammal and poultry

Comparison of Clindamycin, Erythromycin, and Methicillin in Streptococcal Infections in Monkeys

Passive Immunity to Feline Leukemia: Evaluation of Immunity from Dams Naturally Infected and Experimentally Vaccinated

FELINE VIRAL UPPER RESPIRATORY DISEASE Why it Persists!

Domestic Bighorn Sheep Interface Problem Overview and Research. American Sheep Industry Annual Convention Reno, NV January 27-31, 2015

Reproductive Vaccination- Deciphering the MLV impact on fertility

SENSITIVE AND -RESISTANT TUBERCLE BACILLI IN LIQUID MEDIUM SENSITIVITY TESTS

Pathogenesis of Feline Panleukopenia Virus in Susceptible Newborn Kittens

Summary of Product Characteristics

Feline zoonoses. Institutional Animal Care and Use Committee 12/09

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS

Proceeding of the SEVC Southern European Veterinary Conference

Rhipicephalus sanguineus: Vector of a New Spotted Fever

International Journal of Science, Environment and Technology, Vol. 5, No 5, 2016,

Canine and Feline Parvovirus in Animal Shelters

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Burn Infection & Laboratory Diagnosis

Nursing the feline patient with upper respiratory tract disease

Feedlot AIP: What the Heck Causes It?

Difficulties in demonstrating long term immunity in FeLV vaccinated cats due to increasing agerelated resistance to infection

SCIENTIFIC DISCUSSION

FOSTERING CATS. Behavioral Issues

Feline Vaccines: Benefits and Risks

Changing Trends and Issues in Canine and Feline Heartworm Infections

Efficacies of fenbendazole and albendazole in the treatment of commercial turkeys artificially infected with Ascaridia dissimilis

CONTAGIOUS BOVINE PLEURO- PNEUMONIA steps towards control of the disease. Rose Matua -Department of Veterinary Services, Kenya

Attorneys for Plaintiffs Hells Canyon Preservation Council and The Wilderness Society UNITED STATES DISTRICT COURT FOR THE DISTRICT OF IDAHO

Sampling sites for detection of feline herpesvirus-1, feline calicivirus and Chlamydia felis in cats with feline upper respiratory tract disease

COMMON CLINICAL CONDITIONS IN RATS AND MICE

by adding different antibiotics to sera containing

Rx, For use by or on the order of a licensed veterinarian.

and other serological tests in experimentally infected cattle

Effects of Minocycline and Other Antibiotics on Fusobacterium necrophorum Infections in Mice

Feline Immunodeficiency Virus (FIV)

FELINE CORONAVIRUS INFECTIONS. Dr. John R. August Texas A&M University

Calicivirus Protocol Handbook

FELINE CORONAVIRUS (FCoV) [FIP] ANTIBODY TEST KIT

How to control cat flu in a boarding cattery

ASVCP quality assurance guidelines: veterinary immunocytochemistry (ICC)

METRIGUARD. Technical Bulletin

Journal home page:

B. PACKAGE LEAFLET 1

Proceedings of the Southern European Veterinary Conference and Congreso Nacional de AVEPA

AN EVIDENCE-BASED APPROACH TO THE CONTROL OF FELINE PANLEUKOPENIA, FELINE HERPESVIRUS-1, AND FELINE CALICIVIRUS IN SHELTER CATS

Medical bacteriology Lecture 8. Streptococcal Diseases

Micrococcus. May be normal present in upper respiratory tract. - Grow on ordinary media Nutrient agar - Blood agar and. M. luteus.

Cercetări bacteriologice, epidemiologice şi serologice în bruceloza ovină ABSTRACT

Single-Dose Toxicity Study in Beagle or Mixed Breed Dogs. MTD Determination with Repeat Dose Range-Finding in Beagle or Mixed Breed Dogs

Experimental Feline Viral Rhinotracheitis

Bacterial Pneumonia in Sheep, The Domestic Bighorn Sheep Interface, and Research at ADRU

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS


Mastitis and On-Farm Milk Cultures - A Field Study - Part 1

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Feeding Original XPC TM can help reduce Campylobacter in broilers and turkeys

VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill

Medical Bacteriology- Lecture 14. Gram negative coccobacilli. Zoonosis. Brucella. Yersinia. Francesiella

Error! Reference source not found. I. SUMMARY OF PRODUCT CHARACTERISTICS

Role of Antibodies in Immunity to Bordetella Infections

Hemolysis Test for Cattle Vaccinated and Infected with

Providing links to additional websites for more information:

Rapid Diagnostic Test for pet

Course 453. Dr. Soliman Mohammed Soliman Lecturer of Infectious Diseases Dept. of Medicine and Infectious Diseases

Domestic Bighorn Sheep Research American Sheep Industry/ National Lamb Feeders Association Annual Convention Charleston, SC January 22-25, 2014

Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children

EXCEDE Sterile Suspension

TTX - Inject 1: Early warning indicators Part I. Regional Table Top Exercise for Countries of Middle East and North Africa Tunisia; July 2017

against Clinical Isolates of Gram-Positive Bacteria

Washington State University Institutional Animal Care and Use Committee Management of Ulcerative Dermatitis in Mice Approved: 06/27/2018

Summary of Product Characteristics

Transcription:

INFECTION AND IMMUNITY, May 1975, p. 1003-1009 Copyright 0 1975 American Society for Microbiology Vol. 11. No. 5 Printed in U.S.A. Induction of Immunity to Feline Caliciviral Disease DONALD E. KAHN,* EDWARD A. HOOVER, AND JAMES L. BITTLE Department of Veterinary Pathobiology, The Ohio State University, College of Veterinarv Medicine. Columbus, Ohio 43210,* and Pitman-Moore, Inc., Washington Crossing, New Jersey 08560 Received for publication 26 November 1974 Six specific-pathogen-free cats were exposed by aerosol to a feline calicivirus of low virulence (F-9 virus). Homotypic (anti-f-9) seroconversion occurred in all cats by postexposure day 14. The serum of one cat on postexposure day 14 and four of six cats on postexposure day 35 neutralized feline picornavirus isolate no. 255 (FPV-255), a virulent feline calicivirus. Homologous antiviral activity was detected before the appearance of heterologous (anti-fpv-255) activity and always was present in higher titer. Protective immunity was evaluated on postexposure day 35 by aerosol challenge with FPV-255. The pyrexia, depression, dyspnea, oral ulcers, and severe pneumonia produced in two susceptible specific-pathogen-free cats by exposure to FPV-255 did not occur in the cats that had been infected previously with F-9 virus. The study demonstrates that heterotypic protective immunity to feline calicivirus disease can be induced by prior infection with feline calicivirus of low virulence. Feline caliciviruses (FCV) (16) have been isolated from the respiratory tract and visceral organs of domestic cats. Some strains, such as kidney cell degenerating virus (5), are of minimal significance as feline pathogens (2, 12, 15), whereas others induce oral ulcers and pneumonia (9, 10, 12, 14; E. A. Hoover and D. E. Kahn, J. Am; Vet. Med. Assoc., in press). The virulent FCV can produce a substantial disease problem in breeding colonies and laboratory facilities where cats are housed together. Extensive serological cross-reactivity among FCV has been observed in tests using hyperimmune goat and rat sera (8). It is not known whether the protective immunity conferred to cats by previous FCV infection (1) is restricted to homologous virus or if the antigenic determinants shared by more than one FCV serotype can induce heterotypic protective immunity. Studies of the immunological response of the cat to FCV infection have been slowed by the limited availability of susceptible cats. The majority of random-source cats obtained from commercial animal dealers have been infected with FCV (2). This problem has been obviated by the use of specific-pathogen-free (SPF) cats that lack previous immunological experience with FCV antigens as well as subclinical infection with other feline viruses (10, 14). In this study we describe the response of SPF cats to aerosol infection with an FCV of low virulence and the heterotypic protective immunity induced to challenge with a virulent pneumotropic FCV strain. MATERIALS AND METHODS Viruses. FCV strain F-9 was isolated from the pharynx of a cat (3). The 24th tissue culture passage of this virus was used as the immunogen (vaccine virus) in this study. The first 10 passages of F-9 were in primary feline kidney cell cultures; subsequently the virus was propagated in a feline embryonic diploid tongue cell line, FC, Tg (A. Kniazeff, Naval Biological Laboratory, University of California, Berkeley, Calif.). The F-9 viral stock was purified by three successive terminal dilutions and tested to assure its freedom from other viruses and bacteria. The inoculum used titered 105 25 median tissue culture infective doses per 0.1 ml, as calculated by the Spearman- Ktirber method (6). The 5th tissue culture passage FPV-255 (11) was used to challenge the immunity of F-9-exposed (vaccinated) cats. The response of SPF cats following exposure to FPV-255 aerosols has been described (10). The challenge virus, propagated in Crandell feline kidney cell culture (4), titered 1055 median tissue culture infective doses per 0.1 ml. Cats. Eight male SPF cats from the breeding colony developed in the Department of Veterinary Pathobiology were used in the study. The cats, of caesarian-derived, gnotobiotic ancestry (15), have been maintained in isolation as a closed colony free of spontaneous viral diseases since 1966. The cats were between 3 and 4 months of age and were housed in separate cages in a room isolated from other cats during the experimental period. Animal inoculations. Aerosols of the viral inocula were generated by forcing air through a handoperated Devilbiss no. 40 nebulizer (Devilbiss Co., Somerset, Pa.). The heads of unanesthetized cats were enclosed within an 18 cm diameter plastic chamber attached to the mouth of the nebulizer. Each 1003

1004 KAHN, HOOVER, AND BITTLE INFECT. IMMUN. cat was exposed to the viral aerosol for 2 min. Six cats were exposed to F-9 virus at the start of the experiment, designated as postexposure day (PED) 0, and to FPV-255 on PED 35. Two cats that had not experienced F-9 infection were exposed to aerosols of the same FPV-255 inoculum. The 2 nonvaccinates served as indicators of the severity of the FPV-255 challenge. Clinical observations. Cats were examined each morning and afternoon for clinical signs of illness. The rectal temperature of each cat was recorded during each observation period. Sample collection. Swabbings of the nasal, oropharyngeal, conjunctival, and rectal mucosae were collected prior to F-9 exposure and on PED 3, 5, 7, 14, 21, 28, and 35. Swabbings also were collected daily for the first 7 postchallenge days (PCD) and on PDC 15. The method used was the same as that described previously (12). Serum was collected prior to F-9 exposure and at weekly intervals thereafter. Three F-9 vaccinates and the two unvaccinated cats were killed on PCD 8. The three remaining F-9 vaccinates were killed on PCD 15. Each cat was necropsied, and portions of lung, nictitating membrane, tonsil, and nasal turbinate were preserved in buffered 10% formalin for histopathologic evaluation. Samples of' tonsil, nictitating membrane, and lung were collected aseptically for viral isolation studies. Cell culture. The Crandell embryonic feline kidney cell line (4) was used in virological and serological assays. Cultures were seeded into disposable multiple-well plastic trays (Model FB-16-24 TC Disposo Trays, Linbro Chemical Co., Inc., New Haven, Conn.) and incubated at 37 C in an atmosphere containing 5% CO2. Virus isolation. Swab samples and 10% (wt/vol) suspensions of tissue specimens were assayed for FCV by inoculation onto Crandell embryonic feline kidney monolayers. The presence of virus was detected by distinctive cytopathic changes in the monolayer as described previously (12). SN test. Sera were heat-inactivated (56 C, 30 min), TABLE 1. diluted by fourfold increments, and mixed with equal volumes of a viral suspension calculated to contain 100 median tissue culture infective doses per 0.1 ml. Each serum was tested for neutralizing antibody against both F-9 and FPV-255. The median neutralization value (SN50) for each sample was determined by following previously described procedures (12). RESULTS Clinical observations. Small ulcerations of the palatine mucosa of two cats and ulceration of the median cleft of the nostril in two others were the only clinical evidence of illness detected following aerosol exposure to F-9 virus (Table 1). Pyrexia was not detected (Fig. 1). After challenge with FPV-255, no clinical signs of illness were detected in four of the six cats previously exposed to F-9 virus. Mild blepharospasm and a transient rise in rectal temperature (39.4 C) were detected in one cat on PCD 1. One cat that had an ulcerative lesion of the median cleft of the nostril following F-9 exposure developed a similar lesion on PCD 7. Mean rectal temperatures of the vaccinates during the postchallenge period are plotted in Fig. 2. Both unvaccinated cats became febrile, depressed, dyspneic, and developed ulcers of the tongue and hard palate (Fig. 2; Table 2). The illness was typical of FPV-255 infection in susceptible cats (10, 12). Lesions. No macroscopic lesions were present in the lungs of F-9-exposed cats (Fig. 3). In two cats, mild perivascular or peribronchial collections of lymphocytes and plasma cells were observed by histopathological examination. Peribronchiolar infiltration with eosinophils or small, focal accumulations of alveolar macro- Response of susceptible SPF cats to aerosols of F-9 virus Clinical signs of disease Virus isolations PED Pxia Oral-nasal Other signs Pharyngeal Nasal Conjunctival Rectal ulcerationsa of disease swabs swabs swabs swabs 0 0/6h 0/6 0/6 0/6 0/6 0/6 0/6 3 0/6 0/6 0/6 6/6 5/6 1/6 0/6 5 0/6 2/6 0/6 2/6 2/6 1/6 0/6 7 0/6 2/6 0/6 6/6 2/6 0/6 0/6 10 0/6 0/6 0/6 NT, NT NT NT 14 0/6 0/6 0/6 2/6 2/6 0/6 0/6 21 0/6 0/6 0/6 0/6 0/6 0/6 0/6 28 0/6 0/6 0/6 2/6 0/6 0/6 0/6 35 0/6 0/6 0/6 4/6 0/6 0/6 0/6 a Small ulcerations of the palatine mucosa or nostril. Palatine lesions would be inapparent by routine clinical examination and cause no apparent behavioral changes. Numerator, Number positive; denominator, total. NT, Sample not taken.

VOL. 11, 1975 (C) 0 1 2 3 4 5 6 DAY FOLLOWING F9 EXPOSURE FIG. 1. Mean rectal temperatures of SPF cats after aerosol exposure (vaccination) to F-9 FCV. Pyrexia was not detected. 2 3 4 5 6 7 DAY FOLLOWING FPV -255 CHALLENGE FIG. 2. Mean rectal temperature of cats previousl'v exposed to F-9 virus aerosols and susceptible SPF cats after challenge with FPV-255. TABLE 2. FELINE CALICIVIRAL DISEASE IMMUNITY phages were present in two cats. Infiltrations of neutrophils were observed in tonsilar crypt epithelium of four cats and nictitating membrane of three cats. The results are summarized in Table 2. Gross lesions of pneumonia were present in both nonvaccinates. The lesions involved virtually the entire apical and cardial lobes in one cat (Fig. 4). Histopathologic examination revealed severe fibrinopurulent pneumonia with extensive inflammatory edema or alveolar necrosis. The process was typical of FPV-255- induced pulmonary lesions studied previously (9, 10). Ulcerative lesions of the tonsilar crypt epithelium, tongue, and palatine mucosa (Table 2) also were similar to those described previously in FPV-255-infected SPF cats (10). Virus isolation. Cytopathogenic agents were not cultured from nasal, conjunctival, pharyngeal, or rectal swabbings collected prior to F-9 viral exposure. FCV was isolated from swabbings collected after exposure of cats to F-9 virus (Table 1). Virus was isolated from pharyngeal swabbings with greatest frequency, and these were the only samples to contain virus after PED 14. FCV was isolated from pharyngeal swabbings of four cats collected on PED 35, just prior to challenge with FPV-255. The frequency of FCV isolation from swab samples collected from F-9-exposed and unvaccinated cats after FPV-255 challenge is listed in Table 3. FCV was isolated from 75% of the swabbings collected from the F-9-exposed cats on PCD 3. Virus was isolated less frequently from specimens collected subsequently. A simi- Response of F-9-exposed (vaccinated) and unvaccinated SPF cats after aerosol challenge with FPV-255a Lesions Group Cat PklCld Clinical signs of disease Tongue Lug and palatenoti F-9 exposed cats 1 8 None 2 8 Nasal ulceration (PCD 7) + 3 8 Mild blepharospasm and transient, 4 mild pyrexia (PCD 1) 4 15 None 4 5 15 None - ND ND 6 15 None Unvaccinated cats 1 8 Pyrexia (PCD 1 to 6); ulcers of + + + + + tongue and palate; depression; dyspnea 2 8 Similar to above ++±+ + + + N a _, Lesions not detected; 4, peribronchiolar infiltration of eosinophils or small, focal accumulations of macrophages within alveoli; +, lesions present, graded + to +++ according to severity; ND, sample not evaluated microscopically. 1005

1006 KAHN, HOOVER, AND BITTLE INFECT. IMMUN. FIG. 3. Left lobes of the lung of an F-9-vaccinated cat killed 8 days after aerosol challenge with FPV-255. No pulmonary lesions are present. Downloaded from http://iai.asm.org/ on October 3, 2018 by guest FIG. 4. Right lobes of a susceptible SPF cat killed 8 days after aerosol challenge with FPV-255. There is extensive pneumonia involving the anterior and middle lobes (arrows). lar reduction in the frequency of FCV isolation from samples collected from the unvaccinated cats after FPV-255 challenge did not occur. Virus was isolated from the lungs and tonsils of both nonvaccinates and from the nasal turbinate of one cat. In the F-9-exposed cats, FCV could not be isolated from lung samples, but it was cultured from three of six tonsils, one of six nasal turbinates, and one of six nictitating membranes. SN tests. Neutralizing antibody to either F-9 or FPV-255 was not detected in 1:4 dilutions of

VOL. 11, 1975 serum from cats prior to their initial viral exposure. Anti-F-9 (homotypic) activity was present in four of six sera on PED 7. Homotypic antibody was detected in all sera from F-9- exposed cats collected on PED 14 and at subsequent sampling periods. Geometric mean SN50 values for the group of F-9-exposed cats are plotted in Fig. 5. Anti-FPV-255 (heterotypic) neutralizing activity was detected in four of the six sera on PED 35. Heterotypic antibody was first detected in the serum of one cat on PED 14 (SN50 = 1:4), and was detected in the serum of a second on PED 21 (SNso = 1:8). Serum of all TABLE 3. FELINE CALICIVIRAL DISEASE IMMUNITY six cats sampled on PCD 7 neutralized FPV- 255. Geometric mean SN50 values of anti-fpv- 255 activity are plotted in Fig. 5. The deviations of the geometric means of heterotypic titers from those of anti-f-9 titers were significant (P < 0.025) on PED 7, 14, 21, 28, and 35. Following FPV-255 challenge, the differences were not significant (Student's t test [7]). An increase in neutralizing titer to F-9 virus followed challenge with FPV-255 but was less dramatic than the rise in anti-fpv-255 titer (Fig. 5). Serum samples from nonvaccinates collected FCV isolation from swab samples collected from F-9-exposed (vaccinated) and unvaccinated SPF cats after aerosol challenge with FPV-255 F-9 vaccinates Unvaccinated cats PCD Pharyngeal Nasal Conjunctival Rectal Pharyngeal Nasal Conjunctival Rectal swabs swabs swabs swabs swabs swabs swabs swabs 0 4/6a 0/6 0/6 0/6 0/2 0/2 0/2 0/2 1 5/6 3/6 4/6 0/6 2/2 1/2 2/2 0/2 2 5/6 4/6 3/6 1/6 2/2 2/2 2/2 0/2 3 6/6 4/6 4/6 4/6 2/2 2/2 2/2 0/2 4 6/6 5/6 3/6 0/6 2/2 2/2 2/2 0/2 5 3/5 3/5 2/5 2/5 2/2 2/2 2/2 1/2 6 6/6 4/6 2/6 0/6 2/2 2/2 2/2 0/2 7 6/6 2/6 0/6 2/6 2/2 2/2 2/2 0/2 15 3/3 0/3 0/3 0/3 NTP NT NT NT a Numerator, Number positive; denominator, total. b NT, Sample not taken. AEROSOL EXPOSURE TO F9 CALICIVI RUS 3.0 AEROSOL EXPOSURE TO FPV-255' 2.5-2.0- _ ANTI - F9 ANTI-FPV 255 (TITERS EXPRESSED AS THE GEOMETRIC MEAN ± 1 STANDARD DEVIATION ) 1.61±l0.40 1.7±0408 1.57+-0.40 / ~~~~~~1.50, 0±0.44 2.47±0.30 2.31 ±0.50 0.36 1.63±080 1007 (-LOG10) 1.5-1.0-0.5- /0.69+0.40 0.47±0. 0.28±0.44 0.10+0 24.0- w l 0.67±0.57 0 7 14 21 28 35 42 49 DAY FOLLOWING F9 EXPOSURE FIG. 5. Geometric mean neutralization titers of sera from cats sequentially exposed to aerosols of F-9 and FPV-255 caliciviruses. i2

1008 KAHN, HOOVER, AND BITTLE INFECT IMMUN. 7 days af'ter challenge with FPV-255 neutralized homologous virus (SN55 = 1:16 and 1:32). but not F-9 virus. DISCUSSION The one study of' FCV immunity that has been reported determined that once cats had recovered from FCV-induced disease thev remained asymptomatic after re-exposure to the same viral strain (1). Protective immunity could not be demonstrated when convalescent cats were exposed to a heterologous strain of FCV. We have observed that convalescent FPV-255-infected cats are protected from illness upon subsequent exposure to the same virus (D. E. Kahn and E. A. Hoover, unpublished data). Our present f'indings indicate that protective immunity to a highly virulent FCV also can be induced by previous infection with a serologically distinct FCV strain of' minimal virulence (F-9 virus). The contrast in responses of susceptible and vaccinated cats was striking. Although FCV was isolated from swab samples collected from both groups following FPV-255 exposure, vaccinates developed no clinical illness and few lesions, whereas pyrexia, depression, dyspnea, ulcers of' the oral mucosa, and pneumonia occurred in the nonvaccinated cats. The F-9 virus used as an immunogen in this study did not induce signs of respiratory illness. The virulence of this F-9 viral inoculum was reduced compared to a lower tissue culture passage level of the same virus (E. A. Hoover and D. E. Kahn, in press). Further attenuation may be necessary to produce an immunogen that no longer produces ulcerative lesions of the nostril. Serological classification of' various FCV strains remains to be resolved. Comparison of 12 FCV strains by reciprocal neutralization tests using hyperimmune goat antisera indicated broad antigenic overlap among the viruses. In complement-fixation tests employing antisera produced in gnotobiotic rats, eight FCV strains were resolved into seven serologically distinguishable groups (8). Our study indicates that whereas F-9 and FPV-255 may share some common antigenic determinant(s), they are not identical viruses. Homologous antiviral activity was detected before the appearance of heterologous activity and always was present in higher titer. The homologous antibody detected during the early stages of F-9 infection does not fix guinea pig complement but is detectable by a complement-fixation-inhibition test (13). Complement-fixing antibody to F-9 virus was detectable by PED 35 (13). This suggests that the initial species of antibody f'ormed following FCV does not fix complement but is viral strain specific. Later the cat forms antibody that fixes complement and neutralizes heterologous virus (FPV-255). We are conducting reciprocal neutralization tests using sera from cats collected during the first several weeks of' FCV infection. The objective is to determine whether such sera are less cross-reactive than the goat and rat antisera that have been employed previouslv (8). The development of highly specific immune sera would assist materially in the serotyping of FCV strains. Correlation between serological antiviral activity and immunological protection of the convalescent FCV-infected cat when challenged with an antigenically related virus remains to be investigated. Should there be a high correlation, it may prove feasible to substitute serological procedures for animal trials in determining which FCV strains cross-protect. It remains to be determined whether the protective immunity observed to FPV-255 induced by prior F-9 inf'ection resulted from a fortuitous pairing of' FCV strains, or whether this immune state extends to other virulent FCV as well. If' the protective immunity can be shown to be a generalized phenomenon in FCV infection, immunoprophylaxis may prove to be a feasible method for the control of this prevalent viral disease of the cat. Information concerning the development of the feline caliciviral vaccine used in this study will be published separately (J. L. Bittle and W. J. Rubic, manuscript in preparation). ACKNOWLEDGMENTS This investigation was supported bv a grant from Pitman- Moore, Inc. We acknowledge the technical assistance of Jon Edwards and Mary Gillenwater. LITERATURE CITED 1. Bartholomew, P. T., and J. H. Gillespie. 1968. Feline viruses. I. Characterization of four isolates and their effect on young kittens. Cornell Vet. 58:248-265. 2. Bittle, J. L., J. B. Emery, C. J. York, and J. K. McMillen. 1961. Comparative study of feline cytopathogenic viruses and feline panleukopenia virus. Am. J. Vet. Res. 22:374-378. 3. Bittle, J. L., C. J. York, J. W. Newberne, and M. Martin. 1960. Serologic relationship of new feline cvtopathogenic viruses. Am. J. Vet. Res. 21:547-550. 4. Crandell, R. A.. C. G. Fabricant, and W. A. Nelson-Rees. 1973. Development, characterization, and viral susceptibility of a feline (Felis catus) renal cell line (CRFK). In Vitro 9:176-185. 5. Fastier, L. B. 1957. A new feline virus isolated in tissue culture. Am. J. Vet. Res. 18:382-:389. 6. Finney, D. J. 1964. Statistical methods in biological assay, 2nd ed., p. 524-531. Hafner Publishing Co., New York. 7. Fisher, R. A. 1936. Statistical methods for research workers, 6th ed. Oliver and Boyd, London. 8. Gillespie. J. H., and F. W. Scott. 197.3. Feline viral infections. Adv. Vet. Sci. Comp. Med. 17:164-200.

VOL. 11, 1975 FELINE CALICIVIRAL DISEASE IMMUNITY 1009 9. Holzinger, E. A., and D. E. Kahn. 1970. Pathologic features of picornavirus infections in cats. Am. J. Vet. Res. 31:1623-1630. 10. Hoover, E. A., and D. E. Kahn. 1973. Lesions produced by feline picornaviruses of different virulence in pathogen-free cats. Vet. Pathol. 10:307-322. 11. Kahn, D. E., and J. H. Gillespie. 1970. Feline viruses. X. Characterization of a newly-isolated picornavirus causing interstitial pneumonia and ulcerative stomatitis in the domestic cat. Cornell Vet. 60:669-683. 12. Kahn, D. E., and J. H. Gillespie. 1971. Feline viruses: pathogenesis of picornavirus infection in the cat. Am. J. Vet. Res. 32:521-531. 13. Olsen, R. G., D. E. Kahn, E. A. Hoover, N. J. Saxe, and D. S. Yohn. 1974. Differences in acute and convalescent-phase antibodies of cats infected with feline picornaviruses. Infect. Immun. 10:375-380. 14. Povey, R. C., and C. J. Hale. 1974. Experimental infections with feline caliciviruses (picornaviruses) in specific-pathogen-free kittens. J. Comp. Pathol. 84:245-256. 15. Rohovsky, M. W., R. A. Griesemer, and L. G. Wolfe. 1966. The germ-free cat. Lab. Anim. Care 16:52-59. 16. Wildy, P. 1971. Classification and nomenclature of viruses. First report of the international committee of nomenclature of viruses, p. 55. In J. L. Melnick (ed.). Monographs in virology, vol. 5. S. Karger, Basel. Downloaded from http://iai.asm.org/ on October 3, 2018 by guest